Full history for every metric is available with a Kvantra account
Abliva AB (publ) (ABLI.ST)
Key financial summary
Financials in SEK| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | ||
|---|---|---|---|---|---|---|---|
| Total revenue | SEK m | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating profit | SEK m | -97 | |||||
| Net profit | SEK m | -68 | -77 | -60 | -123 | -85 | -96 |
| EPS reported | SEK | -0.09 | |||||
| Operating cashflow per share | SEK | -0.01 | |||||
| Capex per share | SEK | 0.00 | |||||
| FCF per share | SEK | -0.01 | |||||
| Free cash flow | SEK m | -9 | |||||
| Net debt | SEK m | -58 | |||||
| Book value equity | SEK m | 71 | |||||
| Book value per share | SEK | 0.07 | |||||
| Number of shares | m | 1,056.3 | |||||
| DPS (TTM paid) | SEK | 0.00 |
Financial summary
Financials in SEK| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | ||
|---|---|---|---|---|---|---|---|
| Value | |||||||
| P/E TTM | x | - | |||||
| P/B LTM | x | 3.67 | |||||
| P/S LTM | x | 1,892.86 | |||||
| P/FCF LTM | x | -28.52 | |||||
| EV/EBITDA LTM | x | -2.16 | |||||
| EV/Sales LTM | x | 1,475.05 | |||||
| Earnings Yield LTM | % | -36.83% | |||||
| FCF Yield | % | -3.51% | |||||
| Quality | |||||||
| ROE | % | -135.06% | |||||
| ROIC | % | -135.70% | |||||
| Operating margin | % | -70473.0% | |||||
| Gross margin | % | -50132.8% | |||||
| FCF/Sales | % | -6636.5% | |||||
| Growth and momentum | |||||||
| EPS Growth YoY | % | - | |||||
| Sales Growth YoY | % | +341.94% | |||||
| Net Income Growth YoY | % | - | |||||
| FCF Growth | % | - | |||||
| Operating Profit Growth | % | - | |||||
| Dividend and capital structure | |||||||
| Dividend Yield | % | 0.00% | |||||
| Dividend Growth | % | 0.00% | |||||
| Payout Ratio | % | 0.00% | |||||
| FCF/Debt | x | -21.44 | |||||
| Net Debt/EBITDA | x | 0.61 | |||||
| EBIT/Net interest | x | -1,270.37 | |||||
| Net debt/market cap | % | -22.24% | |||||
| Net debt/Equity | x | -0.82 | |||||
| Gross debt/equity | x | 0.01 | |||||
Company overview
Abliva AB (publ), a Swedish biopharmaceutical company founded in Lund in 2000, focuses on developing innovative therapeutic solutions for primary mitochondrial diseases. Its pipeline includes KL1333, currently in Phase 2/3 clinical trials for the long-term management of these conditions, and NV354, which is preparing for clinical studies targeting primary mitochondrial diseases specifically linked to Complex I deficiency. The company is also advancing NeuroSTAT through a Phase 1b/2a clinical study for the treatment of traumatic brain injury. Abliva maintains strategic partnerships with entities such as Isomerase, Yungjin Pharm, the University of Pennsylvania, Children's Hospital of Philadelphia, and Oroboros Instruments. The firm rebranded as Abliva AB (publ) in May 2020, having previously been known as NeuroVive Pharmaceutical AB (publ).
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Abliva AB (publ) (ABLI.ST)
Abliva AB (publ), a Swedish biopharmaceutical company founded in Lund in 2000, focuses on developing innovative therapeutic solutions for primary mitochondrial diseases. Its pipeline includes KL1333, currently in Phase 2/3 clinical trials for the long-term management of these conditions, and NV354, which is preparing for clinical studies targeting primary mitochondrial diseases specifically linked to Complex I deficiency. The company is also advancing NeuroSTAT through a Phase 1b/2a clinical study for the treatment of traumatic brain injury. Abliva maintains strategic partnerships with entities such as Isomerase, Yungjin Pharm, the University of Pennsylvania, Children's Hospital of Philadelphia, and Oroboros Instruments. The firm rebranded as Abliva AB (publ) in May 2020, having previously been known as NeuroVive Pharmaceutical AB (publ).
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free